US Pharma MarketingExclusive: FDA acting chief walks back Makary
Acting FDA chief Diamantas tells DeGette two Makary-era journal articles, on CAR-T trials and a rare disease pathway, were not agency guidance. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
The FDA is continuing to rewind actions by former Commissioner Marty Makary, saying that two medical journal articles published over the last year did not constitute agency policy.
The about-face formally addresses one of the ...
Source: Endpoints News